Qizheng Tibetan Medicine’s 2024 financial report shines: Both revenue and net profit excluding non-recurring items grew at double-digit rates, and its multi-product, omni-channel marketing strategy has yielded remarkable results.

On the evening of April 24, Qizheng Tibetan Medicine (002287.SZ) released its 2024 financial report, reporting operating revenue of 2.338 billion yuan, a year-on-year increase of 14.32%. Operating profit reached 657 million yuan, and net profit attributable to shareholders of the listed company was 582 million yuan. Net profit attributable to shareholders of the listed company excluding non-recurring gains and losses came in at 426 million yuan, representing a year-on-year growth of 15.09%. The company’s business performance continued to grow steadily, reaching yet another new high.

As a leading enterprise in the modernization of Tibetan medicine, Qizheng Tibetan Medicine is deeply rooted in Tibetan medical culture. Relying on diversified product offerings, multidisciplinary coverage, and a multi-tiered strategic layout, it leverages the distinctive therapeutic advantages of Tibetan medicine across various fields to provide users with comprehensive diagnosis and treatment solutions.

The company ranks first in the industry in terms of the inventory of approved Tibetan medicine products. Based on its deep understanding of patient needs, Qizheng Tibetan Medicine has developed a “multi-product, omni-channel marketing” strategy—by leveraging a diversified product portfolio, the company is gradually expanding its market share across various therapeutic areas and providing clinicians with a richer array of specialized treatment options.

According to the financial report, in 2024, the company’s core product for the musculoskeletal system—the pain-relief plaster—focused on key hospitals and expanded its reach across multiple departments and disease areas. The company deepened its engagement in orthopedics while closely collaborating with key departments such as rehabilitation, geriatrics, pain management, and general medicine, continuously broadening its hospital coverage at both higher-tier and grassroots levels. At the same time, the company significantly boosted its online channels, driving substantial growth in B2C and O2O sales. As a result, the market share of the pain-relief plaster continued to consolidate, providing stable support for the company’s overall business growth. The Bai Mai ointment and Ruyi Zhenbao tablets have shown remarkable performance in the musculoskeletal pain relief segment, emerging as new growth drivers. Building on research findings related to the use of Bai Mai ointment in treating diabetic peripheral neuropathy, Bai Mai ointment is not only strengthening its position in orthopedics but also beginning to expand into new departments and new indications. The nationally negotiated medical insurance product, Ruyi Zhenbao tablets, has enhanced expert collaboration through participation in national and provincial annual conferences focused on key disciplines and through Real-World Studies (RWS) on prevalent diseases, continually improving its terminal coverage. In the respiratory field, sales of Shiwai Longdanhua have continued to grow, further enhancing the product’s category influence; in the digestive field, Liuwei Nengxiao tablets have achieved rapid growth and have become a key product within the “Shanwei” family; and in the gynecology field, Honghua Ruyi Wan has experienced relatively fast growth, laying a solid foundation for future expansion.

Leveraging the product’s excellent therapeutic efficacy, the company is adopting a coordinated approach that integrates academic marketing, brand marketing, digital marketing, and channel expansion to build a comprehensive and multi-dimensional professional academic communication system in the healthcare market, thereby serving a broad base of clinical physicians. In the retail market, the company is consolidating B2C, O2O, offline channels, and KA resources to enhance coverage in both markets and achieve significant year-on-year growth in sales.

As of the end of the reporting period, the company held 141 drug approval numbers, centered around 25 exclusive products including Xiao Tong Tie Gao and Bai Mai Soft Ointment. Among these, 60 are OTC products and 3 are classified as state-secret technologies (secret level). The product portfolio covers therapeutic areas such as the musculoskeletal system, nervous system, respiratory system, digestive system, urinary system, as well as cardiovascular and cerebrovascular diseases, gynecology, pediatrics, and dermatology.

In the future, Qizheng Tibetan Medicine will leverage its extensive product portfolio and comprehensive omni-channel coverage to upgrade the modernization of Tibetan medicine, enabling traditional medicine to unlock greater value in the contemporary health sector.

Reporting media: Daily Economic News

Report link: https://m.nbd.com.cn/articles/2025-04-24/3847721.html